Mayne just what the medicine market needs

Mayne's new drug is well received by the market but is not a significant but is not a major earnings driver for the medium term.

News that Mayne Pharma Group (MYX) will start selling an authorised generic drug in the US has sent the stock surging to a more than two-year high this morning.

The drug supplier is now able to tap into a market worth around $US24 million a year with its authorised generic doxycycline hyclate tablet, which is used to treat certain types of bacterial infections.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles